UNITED STATES INTERNATIONAL TRADE COMMISSION
`Washington, D.C.
`
`Before The Honorable Clark S. Cheney
`Administrative Law Judge
`
`
`
`In the Matter of
`
`
`
`
`
`
`
`Investigation No. 337-TA-1207
`
`CERTAIN PRE-FILLED SYRINGES
`FOR INTRAVITREAL INJECTION AND
`COMPONENTS THEREOF
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`JOINT DISCLOSURE OF PROPOSED CLAIM CONSTRUCTIONS
`
`Pursuant to Ground Rule 7.1 and the Procedural Schedule (Order No. 8), Complainants
`
`Novartis Pharma AG, Novartis Pharmaceuticals Corporation, and Novartis Technology LLC
`
`(“Complainants”), Respondent Regeneron Pharmaceuticals, Inc. (“Respondent”), and the
`
`Commission Investigative Staff (“the Staff”) (collectively, “the Parties”) attach hereto: (1) a joint
`
`list of two disputed terms of the asserted claims of U.S. Patent No. 9,220,631 (“the ’631 patent”)
`
`and the proposed constructions thereof, and (2) a joint list of three claim terms whose meanings
`
`are not disputed.
`
`
`
`
`
`
`
`Regeneron Exhibit 1071.001
`Regeneron v. Novartis
`IPR2020-01317
`
`
`Washington, D.C.
`
`Before The Honorable Clark S. Cheney
`Administrative Law Judge
`
`
`
`In the Matter of
`
`
`
`
`
`
`
`Investigation No. 337-TA-1207
`
`CERTAIN PRE-FILLED SYRINGES
`FOR INTRAVITREAL INJECTION AND
`COMPONENTS THEREOF
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`JOINT DISCLOSURE OF PROPOSED CLAIM CONSTRUCTIONS
`
`Pursuant to Ground Rule 7.1 and the Procedural Schedule (Order No. 8), Complainants
`
`Novartis Pharma AG, Novartis Pharmaceuticals Corporation, and Novartis Technology LLC
`
`(“Complainants”), Respondent Regeneron Pharmaceuticals, Inc. (“Respondent”), and the
`
`Commission Investigative Staff (“the Staff”) (collectively, “the Parties”) attach hereto: (1) a joint
`
`list of two disputed terms of the asserted claims of U.S. Patent No. 9,220,631 (“the ’631 patent”)
`
`and the proposed constructions thereof, and (2) a joint list of three claim terms whose meanings
`
`are not disputed.
`
`
`
`
`
`
`
`Regeneron Exhibit 1071.001
`Regeneron v. Novartis
`IPR2020-01317
`
`
`
`I.
`
`Identification of ten terms for construction pursuant to Ground Rule 7.1:
`
`No.
`
`Claim Term Proposed
`By
`
`Claim
`
`Novartis’s
`Proposed
`Construction
`
`Regeneron’s
`Proposed
`Construction
`
`OUII Staff’s
`Proposed
`Construction
`
`“about 1 μg to
`100 ug
`silicone oil”
`(claim 1)
`“about 3 μg to
`about 100 ug
`silicone oil”
`(claim 3)
`“about 1-50
`μg silicone
`oil” (claim
`22)
`
`“less than
`about 11N”
`(claim 1, 16)
`“less than
`about 5N”
`(claim 14)
`
`1.
`
`2.
`
`
`
`Resp.
`
`1, 3, 22
`
`Plain
`meaning.
`
`Indefinite.
`
`Plain and
`ordinary
`meaning.
`
`Resp.
`
`1, 14, 16 Plain
`meaning.
`
`Indefinite.
`
`Plain and
`ordinary
`meaning.
`
`
`
`Regeneron Exhibit 1071.002
`Regeneron v. Novartis
`IPR2020-01317
`
`
`
`II.
`
`Proposed constructions for terms on which the parties agree:
`
`
`
`Further, the following claim constructions for terms and phrases of the asserted claims of
`
`the asserted patent are agreed amongst the Parties:
`
`Claim
`
`Term for
`Construction
`
`4
`
`1
`
`“the silicone oil is
`DC365 emulsion”
`“VEGF-antagonist”
`
`11
`
`“non-antibody
`VEGF antagonist”
`
`Agreed-to Construction
`
`“The silicone oil is applied as a component of
`DC365 emulsion.”
`“A substance capable of blocking or inhibiting
`the biological action of vascular endothelial
`growth factor.”
`
`
`“A VEGF-antagonist that is not an antibody.”
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Regeneron Exhibit 1071.003
`Regeneron v. Novartis
`IPR2020-01317
`
`
`
`Dated: October 9, 2020
`
`
`
`
`Dated: October 9, 2020
`
`Respectfully Submitted,
`
`/s/ Elizabeth J. Holland
`Elizabeth J. Holland
`Calvin Wingfield
`Linnea Cipriano
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018-1405
`Phone: (212) 813-8800
`Email: EHolland@goodwinlaw.com
`Email: CWingfield@goodwinlaw.com
`Email: LCipriano@goodwinlaw.com
`Email: DG-NovartisPFS@goodwinlaw.com
`
`Mark G. Davis
`William James
`Patrick J. McCarthy
`Myomi T. Coad
`GOODWIN PROCTER LLP
`1900 N Street, N.W.
`Washington, D.C. 20036-1612
`Phone: (202) 346-4000
`Email: MarkDavis@goodwinlaw.com
`Email: WJames@goodwinlaw.com
`Email: PMcCarthy@goodwinlaw.com
`Email: MCoad@goodwinlaw.com
`Email: DG-NovartisPFS@goodwinlaw.com
`
`Joshua Weinger
`GOODWIN PROCTER LLP
`100 Northern Avenue
`Boston, MA 02210
`Phone: (617) 570-1000
`Email: JWeinger@goodwinlaw.com
`Email: DG-NovartisPFS@goodwinlaw.com
`
`Counsel for Complainants
`
`Respectfully Submitted,
`
`/s/ W. Peter Guarnieri
`Margaret Macdonald, Director
`Anne Goalwin, Supervisory Attorney
`
`Regeneron Exhibit 1071.004
`Regeneron v. Novartis
`IPR2020-01317
`
`
`
`
`
`
`Dated: October 9, 2020
`
`W. Peter Guarnieri, Investigative Attorney
`U.S. International Trade Commission
`The Office of Unfair Import Investigations
`500 E Street, S.W., Suite 401
`Washington, D.C. 20436
`Phone: (202)-731-0016
`Email: Peter.Guarnieri@usitc.gov
`
`Respectfully Submitted,
`
`/s/ Anish R. Desai
`Elizabeth S. Weiswasser
`Anish R. Desai
`Natalie C. Kennedy
`Andrew P. Gesior
`WEIL, GOTSHAL & MANGES LLP
`767 5th Avenue
`New York, NY 10153
`Telephone: (212) 310-8000
`
`Brian E. Ferguson
`Robert T. Vlasis
`Christopher M. Pepe
`Matthew D. Sieger
`Priyata Y. Patel
`WEIL, GOTSHAL & MANGES LLP
`2001 M Street, Suite 600
`Washington, DC 20036
`Telephone: (202) 682-7000
`Regeneron_337ITC_Service@weil.com
`
`Counsel for Regeneron Pharmaceuticals, Inc.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Regeneron Exhibit 1071.005
`Regeneron v. Novartis
`IPR2020-01317
`
`
`
`CERTIFICATE OF SERVICE
`
`I, Tessa Mager, hereby certify that on this 9th day of October, 2020, a copy of the
`foregoing was filed/served upon the following
`
`
`Via EDIS
`
`Via Electronic Mail
`
`Via Electronic Mail
`
`Via Electronic Mail
`
`The Honorable Lisa R. Barton
`Secretary to the Commission
`U.S. International Trade Commission
`500 E Street, S.W., Suite 112
`Washington, D.C. 20436
`
`The Honorable Clark S. Cheney
`Administrative Law Judge
`U.S. International Trade Commission
`500 E Street, S.W.
`Washington, D.C. 20436
`Cheney337@usitc.gov
`
`W. Peter Guarnieri
`The Office of Unfair Import Investigations
`U.S. International Trade Commission
`500 E Street, S.W., Suite 401
`Washington, D.C. 20436
`Peter.Guarnieri@usitc.gov
`
`Elizabeth S. Weiswasser
`Anish R. Desai
`Natalie C. Kennedy
`Andrew P. Gesior
`WEIL, GOTSHAL & MANGES LLP
`767 5th Avenue
`New York, NY 10153
`Telephone: (212) 310-8000
`
`Brian E. Ferguson
`Robert T. Vlasis
`Christopher M. Pepe
`Matthew D. Sieger
`Priyata Y. Patel
`WEIL, GOTSHAL & MANGES LLP
`2001 M Street, Suite 600
`Washington, DC 20036
`Telephone: (202) 682-7000
`Regeneron_337ITC_Service@weil.com
`
`Counsel for Regeneron Pharmaceuticals, Inc.
`
`Regeneron Exhibit 1071.006
`Regeneron v. Novartis
`IPR2020-01317
`
`
`
`/s/ Tessa S. Mager
`Tessa S. Mager
`Paralegal
`
`
`
`
`
`Regeneron Exhibit 1071.007
`Regeneron v. Novartis
`IPR2020-01317
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
